World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
89
Citations
37939
World Ranking
1101
National Ranking
96

Medicine

D-Index
89
Citations
37975
World Ranking
12495
National Ranking
1174

Karl S. Peggs publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Karl S. Peggs sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 350 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Karl S. Peggs D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Karl S. Peggs sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 89 D-Index — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Karl S. Peggs is affiliated with University College London in the United Kingdom. Their research primarily focuses on the field of Medicine, with a strong concentration on Oncology and Immunology. They contribute extensively to subfields such as Epidemiology, Hematology, and Public Health, Environmental and Occupational Health.

The main topics covered in their work include:

  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Cytomegalovirus and herpesvirus research
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Hematopoietic Stem Cell Transplantation
  • Acute Lymphoblastic Leukemia research

Their publication record features numerous papers in leading scientific venues. Frequent publication venues include:

  • Blood
  • Nature
  • Nature Cancer
  • Immunity
  • Journal of Clinical Oncology

Some of their recent papers are:

  • The evolution of lung cancer and impact of subclonal selection in TRACERx, 2023, Nature
  • Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells, 2020, Immunity
  • The evolution of non-small cell lung cancer metastases in TRACERx, 2023, Nature
  • CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity, 2020, Nature Cancer
  • Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, 2021, Journal of Clinical Oncology

Karl S. Peggs has collaborated frequently with several researchers, including:

  • Claire Roddie
  • Sergio A. Quezada
  • Maria A. V. Marzolini
  • Maeve O'Reilly
  • Martin Pulé

Best Publications

  • Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

    Nicholas McGranahan;Nicholas McGranahan;Andrew J. S. Furness;Rachel Rosenthal;Sofie Ramskov

  • ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

    Daniel W. Lee;Bianca D. Santomasso;Frederick L. Locke;Armin Ghobadi

  • Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

    Christopher Abbosh;Nicolai J. Birkbak;Nicolai J. Birkbak;Gareth A. Wilson;Gareth A. Wilson;Mariam Jamal-Hanjani

  • Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.

    Tyler R. Simpson;Fubin Li;Welby Montalvo-Ortiz;Manuel A. Sepulveda

  • Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

    Karl S. Peggs;Sergio A. Quezada;Cynthia A. Chambers;Alan J. Korman

  • Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

    Sergio A. Quezada;Tyler R. Simpson;Karl S. Peggs;Taha Merghoub

  • Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

    Waseem Qasim;Hong Zhan;Sujith Samarasinghe;Stuart Adams

  • Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies

    Laurent Poirot;Brian Philip;Cécile Schiffer-Mannioui;Diane Le Clerre

  • Checkpoint blockade in cancer immunotherapy

    Alan J. Korman;Karl S. Peggs;James P. Allison

  • CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

    Sergio A. Quezada;Karl S. Peggs;Michael A. Curran;James P. Allison

  • In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.

    Panagiotis D Kottaridis;Donald W Milligan;Rajesh Chopra;Ronjon Chakraverty

  • Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

    Karl S Peggs;Stephanie Verfuerth;Arnold Pizzey;Naeem Khan

  • Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

    Frederick Arce Vargas;Andrew J S Furness;Kevin Litchfield;Kroopa Joshi

  • Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.

    Karl S Peggs;Sergio A Quezada;Alan J Korman;James P Allison

  • Epitope Landscape in Breast and Colorectal Cancer

    Neil H. Segal;D. Williams Parsons;Karl S. Peggs;Victor Velculescu

  • Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.

    Frederick Arce Vargas;Andrew J.S. Furness;Andrew J.S. Furness;Isabelle Solomon;Kroopa Joshi;Kroopa Joshi

  • A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy.

    Brian Philip;Evangelia Kokalaki;Leila Mekkaoui;Simon Thomas

  • High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.

    Suparno Chakrabarti;Stephen Mackinnon;Rajesh Chopra;Panagiotis D Kottaridis

  • Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

    Ronjon Chakraverty;Karl S Peggs;Rajesh Chopra;Donald W Milligan

  • Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

    Unknown

  • Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.

    Karl S Peggs;Ann Hunter;Rajesh Chopra;Anne Parker

Frequent Co-Authors

David C. Linch
David C. Linch University College London
Emma Morris
Emma Morris University College London
Sergio A. Quezada
Sergio A. Quezada University College London
Anthony H. Goldstone
Anthony H. Goldstone University College Hospital
Charles Swanton
Charles Swanton The Francis Crick Institute
Donald Milligan
Donald Milligan University of Birmingham
Nigel H. Russell
Nigel H. Russell University of Nottingham
Charles Craddock
Charles Craddock Queen Elizabeth Hospital Birmingham
Nicholas McGranahan
Nicholas McGranahan University College London
Benjamin M. Chain
Benjamin M. Chain University College London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in immunology, expanding your education through related healthcare degrees can open up diverse career opportunities. Many professionals explore nursing pathways to enhance their understanding of immunological principles in patient care. Programs like the doctorate in nursing salary overview highlight the financial benefits of advancing to doctoral-level nursing roles, particularly in specialized fields.

Transitioning from a Family Nurse Practitioner (FNP) to an Acute Care Nurse Practitioner (ACNP) is a popular route for those seeking more specialized clinical roles. Resources on acnp programs provide clear guidance on how to make this switch effectively, aligning well with interests in acute immunological conditions.

Accelerated educational options, such as accelerated np programs online, are designed for professionals aiming to fast-track their careers without compromising on quality education. These programs are especially valuable for those with prior healthcare experience wanting to specialize quickly.

For individuals without a nursing background, 12-month accelerated nursing programs online for non nurses offer a streamlined path into nursing with the potential to focus on immunology-related specialties later in their careers.

Best Scientists Citing Karl S. Peggs

Trending Scientists

Recently Published Articles